Rare diseases Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
19:57
Jan 09
Jan 09
Biotech momentum broadens beyond GLP-1
Biotech momentum is broad and is not just a GLP-1 obesity-drug story. The space is diverse and gains can come from many therapeutic categories, with oncology, rare diseases, cardiovascular, and inflammation among the most topical areas; the trend should continue.
HIGH
About Rare diseases Investor Commentary
Across the available history and selected sources, Buzzberg tracks Rare diseases across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Jared Holz.